Nogapendekin Alfa Biosimilar Recombinant Protein (IL-15Rα) for Research
Pre-Made Nogapendekin Alfa Biosimilar, Recombinant Protein targeting IL15RA: Recombinant therapeutic protein targeting CD215 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inogapendekin alfa is recombinant human IL-15 with an amino acid substitution (Asn72Asp/N72D) that enhances its agonist activity at the IL-15Rβγc complex. IL-15N72D increases biological activity by 4-5-fold compared to the wild type cytokine. Inogapendekin alfa enhance the immunity and inhibit viral infections.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-928-1mg | 1mg | 3090 |
| GMP-Bios-INN-928-10mg | 10mg | |
| GMP-Bios-INN-928-100mg | 100mg | |
| GMP-Bios-INN-928-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Nogapendekin Alfa Biosimilar, Recombinant Protein targeting IL15RA: Recombinant therapeutic protein targeting CD215 |
| INN Name | Nogapendekin Alfa |
| Target | IL15RA |
| Format | Recombinant Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IL15 (interleukin 15, IL-15) variant N72>D |
| VD LC | IL15 (interleukin 15, IL-15) variant N72>D |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Altor BioScience (FL USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |

